A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2002
11/14/2002	WO2002090304A1 Stable solution of reduced coenzyme q
11/14/2002	WO2002089916A1 Method of preventing type 2 diabetes with aerosolized insulin
11/14/2002	WO2002089855A1 Peroral transduction of hepatocytes in the treatment of disease
11/14/2002	WO2002089853A2 Compositions having enhanced pharmacokinetic characteristics
11/14/2002	WO2002089848A2 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
11/14/2002	WO2002089825A1 Medicinal herbal compounds for the prevention and treatment of diabetes
11/14/2002	WO2002089816A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002	WO2002089811A1 Benzo[d]azepine derivatives as 5-ht6 receptor antagonists.
11/14/2002	WO2002089800A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/14/2002	WO2002089793A1 Sulfonamides
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089785A1 Sulfonamides
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089781A2 Methods of treating hyperlipidemia
11/14/2002	WO2002089770A2 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
11/14/2002	WO2002089743A2 Use of compositions for treating rosacea
11/14/2002	WO2002089740A2 Sulfonamides
11/14/2002	WO2002089729A2 Fused heterocyclic compounds
11/14/2002	WO2002081453A8 Thiohydantoins and use thereof for treating diabetes
11/14/2002	WO2002074326A3 Urocortin-iii and uses thereof
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002	WO2002055152A8 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002010151A3 Method for producing lipoic acid and dihydrolipoic acid
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169317 Oxazinocarbazoles for the treatment of CNS diseases
11/14/2002	US20020169287 Nucleotide sequences coding polypeptide for use in the treatment of eating, dieteticad energy disorders
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002	US20020169194 Treating vision defects
11/14/2002	US20020169192 Peroxisome proliferator activator receptor (PPAR); amino-ethyl- phenyl derivatives
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002	US20020169163 1,2,3,4-tetrahydro-pyrazino(1,2-a)indole derivatives useful in treating obesity, central nerveous system diosrders, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169157 An aromatic or heteroaromatic amino acid derivative, used for treating disorders related to overexpression of protein tyrosine phosphatase-1B
11/14/2002	US20020169155 A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169134 Use of substituted azetidinone compounds for the treatment of sitosterolemia
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168631 Random gene unidirectional antisense library
11/14/2002	US20020168434 Cyclooxygenase inhibitor; anticancer agents, Alzheimer's disease, central nervous system disorders
11/14/2002	US20020168427 Plant extract
11/14/2002	US20020168413 Microstructure grains; fine particle size
11/14/2002	US20020168411 Spill resistant pharmaceutical system
11/14/2002	US20020168406 Gel overcoated with polylysine
11/14/2002	US20020168381 Mixture of bone protein and ethylene oxide-propylene oxide copolymer; in situ administering
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	DE10213304A1 Topical pharmaceutical composition having carrier system forming lamellar double membrane structure with water, providing good skin barrier permeation and high bioavailability without side-effects
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	DE10116829A1 Neuropeptid bindende Nukleinsäuren Neuropeptide binding nucleic acids
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446458A1 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	CA2446437A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446394A1 Insulinotropic peptide derivatives
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446351A1 Fused heterocyclic compounds
11/14/2002	CA2446161A1 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
11/14/2002	CA2445944A1 Method of preventing type 2 diabetes with aerosolized insulin
11/14/2002	CA2445713A1 A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
11/14/2002	CA2445504A1 Methods of treating hyperlipidemia
11/14/2002	CA2444718A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002	CA2435142A1 Kinases and phosphatases
11/13/2002	EP1256582A1 1h-imidazopyridine derivatives
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256350A1 New toralactone and its derivation and the use of decreasing blood-fat and losing weight
11/13/2002	EP1256342A1 Hypoglycemics comprising organic zinc (ii) complexes
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255833A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255819A2 Human kinases
11/13/2002	EP1255779A2 Identification of modulators of gpr41 or gpr42 activity
11/13/2002	EP1255764A1 Purine derivatives
11/13/2002	EP1255752A2 Pyrrole substituted 2-indolinone protein kinase inhibitors
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255748A1 Beta-alanine derivatives and their use as receptor antagonists
11/13/2002	EP1255742A1 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors
11/13/2002	EP1255736A2 Substituted piperazine derivatives and their use as inhibitors of the microsomal triglyceride transfer protein (mtp)
11/13/2002	EP1255732A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
11/13/2002	EP1255724A1 Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament or a diagnostic reagent and medicaments containing said compounds
11/13/2002	EP1255718A1 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
11/13/2002	EP1255566A2 Preparation of aqueous clear solution dosage forms with bile acids
11/13/2002	EP1255561A2 Proteosome influenza vaccine
11/13/2002	EP1255545A2 L-arginine in combination with other compounds for treating cardiovascular diseases
11/13/2002	EP1255542A1 Substituted amino acids as neutral sphingomyelinase inhibitors
11/13/2002	EP1255536A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase
11/13/2002	EP1255456A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall
11/13/2002	EP1255452A2 A method for maintaining or improving the synthesis of mucins

1 ... 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 ... 1298